Physician profile
Chante Ruffin
NPI 1710142773
$282.85
in general payments reported to CMS, 2019-2025
9 companies · $29.49 in 2025
The $29.49 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.64 · 2021: $26.22 · 2022: $68.56 · 2023: $36.07 · 2024: $43.87 · 2025: $29.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $92.64 | 2019-2024 | Jornay Pm |
| Corium, LLC | $42.65 | 2022-2024 | Azstarys |
| Global Blood Therapeutics, INC. | $35.02 | 2022 | |
| Tris Pharma INC | $29.68 | 2019-2025 | Dyanavel Xr |
| Rhodes Pharmaceuticals L.P. | $28.19 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.96 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.49 | 2025 | Qelbree |
| Sanofi Pasteur INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chante Ruffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.